Therapy for subarachnoid hemorrhage and ischemia
US9241970B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Feb 22, 2013 |
| Grant date | Jan 26, 2016 |
| Priority date | — |
| Expiry date | Feb 22, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2871
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery. Rupture is associated with higher mortality or increased debilitation if a subject survives. The trial provided evidence of significant benefit in subjects with and without aneurysm rupture before endovascular was surgery performed. Surprisingly, the subjects benefiting most from treatment as judged both by pathology and neurocognitive outcome were those in which the aneurysm had ruptured causing a subarachnoid hemorrhage. These data constitute evidence that a PSD-95 inhibitor is beneficial not only in ischemic and hemorrhagic stroke but in forms of hemorrhage in or affecting the CNS, particularly, subarachnoid hemorrhage.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.